|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy显示文摘AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer.METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin(85 mg/m2 in over 120 min) followed by leucovorin(400 mg/m2 in over 120 min), with the addition, after 30 min of irinotecan(180 mg/m2 in over 90 min) then 5 fluorouracil(5FU)(400 mg/m2 administred intravenous bolus), followed by 5FU(2400 mg/m2 intraveinous infusion over 46 h) repeated every 2 wk. Geriatric parameters were recorded at the beginning. Toxicities were evaluated with the Common Terminology Criteria for Adverse Events 4.03. Tumor response was evaluated by CT scan. Treatment continued until disease progression, unacceptable toxicities or patient refusal.RESULTS Fifty-two patients aged from 70 to 87 years were treated by FOLFIRINOX, 34 had colorectal cancer and 18 had pancreatic cancer. Most of them were in good general condition, 82.7% had a 0-1 performance status and 61.5% had a Charlson Comorbidity Index < 10. The most frequent severe toxicities were neutropenia(17 patients, n = 32.7%) and diarrhea(35 patients n = 67.3%); 10 of the case of neutropenia and 5 of diarrhea registered a grade 4 toxicity. Thirty-nine patients(75%) initially received an adapted dose of chemotherapy. The dosage was adjusted for 26% of patients during the course of treatment. Tumor response evaluated by RECIST criteria showed a controlled disease for 25 patients(48.1%), a stable disease for 13 and a partial response for 12 patients. Time under treatment was higher for colorectal cancer with a median time of 2.44 mo(95%CI: 1.61-3.25). Overall survival was 43.88 mo for colorectal cancer and 12.51 mo for pancreatic cancer. In univariate or multivariate analysis, none of geriatric parameters were linked to overall survival. Only the type of tumor(pancreatic/colorectal) was linked in both analysis.CONCLUSION For people over 70 years old, FOLFIRINOX regimen seems to induce manageable toxicities but similar, even higher, median survival rates compared to younger people. | Jean-Florian Guion-Dusserre Aurélie Bertaut Fran?ois Ghiringhelli Julie Vincent Valérie Quipourt Sophie Marilier Zoé Tharin Leila Bengrine-Lefevre | 2016 | World Journal of Gastroenterology2016，22，42： | 2 |
| 2 | Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients显示文摘AIM: To establish whether chemotherapy-induced neutropenia is predictive of better outcome in patients with metastatic colorectal cancer(mCRC). METHODS: Survival and patient characteristics from consecutive mCRC patients treated in the Centre Georges Francois Leclerc, Dijon, France between January 2001 and December 2011 were analyzed. Patient and tumor characteristics, hematological toxicity(neutropenia, anemia, and thrombocytopenia), and type of chemotherapy received were recorded. RESULTS: We retrospectively analyzed data from 399 consecutive patients with mCRC who received at least one line of chemotherapy. Median follow up was 6.3 years. Eighty-eight percent of the patients received more than two lines of chemotherapy. By univariate analysis, whatever their grade, neutropenia and thrombocytopenia occurring during the first two lines of chemotherapy were significantly associated with better overall survival(HR = 0.55, 95%CI: 0.43-0.70, P < 0.0001 and HR = 0.70, 95%CI: 0.56-0.88, P = 0.025 respectively). In contrast, anemia during chemotherapy was significantly associated with poorer overall survival(HR = 1.9, 95%CI: 1.22-2.97, P = 0.005). Multivariate analysis revealed that both neutropenia and thrombocytopenia were significantly associated with better overall survival: HR = 0.43, 95%CI: 0.29-0.64, P < 0.0001 and HR = 0.69, 95%CI: 0.49-0.98, P = 0.036, respectively. CONCLUSION: These data suggest that occurrence of neutropenia or thrombocytopenia during first- or second-line chemotherapy for mCRC is associated with better survival. | Laurie Rambach Aurelie Bertaut Julie Vincent Veronique Lorgis Sylvain Ladoire Francois Ghiringhelli | 2014 | World Journal of Gastroenterology2014，20，6： | 2 |
| 3 | Structure and ferrimagnetism of the ilmenite compound MnNiO3显示文摘 | Bertaut F Forrat F | 1958 | Journal of Applied Physics Journal of Applied Physics1958，29，： | 1 |
| 4 | Why do So Few Hold Stocks显示文摘 | Haliassos Michael Carol C Bertaut | 1995 | Economic Journal1995，105，432： | 1 |
| 5 | Etudes de niobates et tantalates de metaux de transition bivalents显示文摘 | BERTAUT E F CORLISS L FORRAT F | 1961 | J Phys Chem Solids1961，21，： | 1 |
| 6 | Etude de niobates et tantalates de metaux de transition bivalents显示文摘 | BERTAUT E F CORLISS L FORRAT F | 1961 | Journal ofPhysics and Chemistry of Solids1961，21，34： | 1 |
| 7 | Substitution dans leshexaferrites de lion Fe3+par Al3+,Ga3+,Cr3+显示文摘 | Bertaut E F Deschamps A Pauthenet R | 1959 | J Phys Radium1959，20，： | 1 |
| 8 | Magnetic studies of the metallic perovskite-type compounds of manganese 显示文摘 | Fruchart D Bertaut E F | 1978 | Journal of Physical Society of Japan1978，44，3： | 1 |
| 9 | Structure magnetique de MnYO3 显示文摘 | Bertaut E F Mercier M | 1963 | Phys Lett1963，5，1： | 1 |
| 10 | Magnetic studies of the metallicperovskite-type compounds of manganese显示文摘 | FRUCHART D BERTAUT E F | 1978 | J Phys Soc Jpn1978，44，3： | 1 |
| 11 | 显示文摘 | Eddine M N Bertaut E F | 1977 | Solid State Communications1977，23，3： | 1 |
| 12 | Substitution dans leshexaferrites de lion Fe3+par Al3+,Ga3+,Cr3+显示文摘 | Bertaut E F Deschamps A Pauthenet R | 1959 | J Phys Radium1959，20，： | 1 |
| 13 | 显示文摘 | Bertaut E F Mareschal J | 1967 | Solid State Commun1967，5，： | 1 |
| 14 | Recent Developmentsin Cross-border Investment in Securities显示文摘 | Carol C Bertaut William L Griever | 2004 | Federal Re-serve Board Bulletin2004，，： | 1 |
| 15 | 显示文摘 | Bertaut E F Mareschal J Pauthenet R | 1976 | Rebouillet Bull Soc Ceram1976，75，： | 1 |
| 16 | Substitution dans les hexaferrites de l' ion Fe^3+ par Al^3+,Ga^3+,Cr^3+显示文摘 | Bertaut E F Deschamps A Pauthenet R | 1959 | J Phys Radium1959，20，： | 1 |
| 17 | On ferrites, theory and practice 显示文摘 | BERTAUT E F | 1950 | J Phys Radium1950，11，5： | 1 |
| 18 | 显示文摘 | Yakel H L Koehler W D Bertaut E F | 1963 | Acta Crystallogr1963，16，： | 1 |
| 19 | Substitution dans les hexaferrites de Fion Fe par AI3', Ga', Cr3显示文摘 | Bertaut E F Deschamps A Pauthenet R | 1959 | j Phys Radium1959，20，23： | 1 |
| 20 | Credit Cards:Facts and Theories显示文摘 | Bertaut C C Haliassos M | | 0，，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员